TY  - JOUR
T1  - VItamin d therapy and cardiac function in chronic kidney disease
AU  - Fourtounas C
Y1  - 2012/06/06
N1  - 10.1001/jama.2012.4168
JO  - JAMA
SP  - 2253
EP  - 2253
VL  - 307
IS  - 21
N2  - 
To the Editor: The Paricalcitol Capsule Benefits in Renal Failure-Induced Cardiac Morbidity (PRIMO) trial by Dr Thadhani and colleagues1 failed to show any improvement in left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) after daily oral administration of paricalcitol for 48 weeks. Similar outcomes have been reported in other prospective studies of patients with CKD receiving erythropoiesis-stimulating agents.2- 3

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.4168
UR  - http://dx.doi.org/10.1001/jama.2012.4168
ER  -